Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02581137 · ClinicalTrials.gov registry record · Phase 2
Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion
A Phase 2 study of Oral Leukoplakia and Oral Cavity Carcinoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 4
- Study locations
NCT02581137 is a Phase 2 study of Oral Leukoplakia and Oral Cavity Carcinoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 26 participants, below the 44-participant average among 4 other Oral Leukoplakia trials with a reported enrollment target (41% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT02581137, a Phase 2 study of Oral Leukoplakia and Oral Cavity Carcinoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 4
- Study locations
Study Summary
This phase IIa trial studies how well metformin hydrochloride works in preventing oral cancer in patients with an oral premalignant lesion (oral leukoplakia or erythroplakia). Oral premalignant lesions look like red or whitish plaques or lesions in the mouth that do not rub off and can be associated with a higher risk of cancer. Metformin hydrochloride may help prevent oral cancer from forming in patients with an oral premalignant lesion.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Metformin Hydrochloride
Study Locations (4)
British Columbia
- BC Cancer Research Centre - Vancouver
- University of British Columbia Hospital - Vancouver
California
- UC San Diego Medical Center - Hillcrest - San Diego
Minnesota
- University of Minnesota/Masonic Cancer Center - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2016-06-10 |
| Est. Completion | 2026-12-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02581137
The ClinicalTrials.gov registry entry for NCT02581137 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 44-participant average among 4 other Oral Leukoplakia trials with a reported enrollment target (41% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Oral Leukoplakia appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02581137 reports 4 study locations spanning 3 distinct geographic areas - top geographies include British Columbia, California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02581137 about?
NCT02581137 is a clinical study titled "Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion". This phase IIa trial studies how well metformin hydrochloride works in preventing oral cancer in patients with an oral premalignant lesion (oral leukoplakia or erythroplakia). Oral premalignant lesions look like red or whitish plaques or lesions in the mouth that do not rub off and can be associated...
What is the current status of trial NCT02581137?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2016-06-10. Estimated completion is 2026-12-19.
What conditions does trial NCT02581137 study?
This clinical trial studies the following conditions: Oral Leukoplakia, Oral Cavity Carcinoma, Erythroplakia, Hyperplasia.
What interventions are being tested in trial NCT02581137?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Metformin Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02581137?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02581137 being conducted?
This trial has 4 study locations across California, Minnesota, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oral Leukoplakia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia
RECRUITING · Phase 2
-
Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia
ACTIVE NOT RECRUITING · Phase 2
-
Fenretinide Mucoadhesive Patch: Evaluation of Oral Cancer Prevention Efficacy in Adults With Premalignant Oral Lesions.
RECRUITING · Phase 1
-
Biomarkers for Oral Cancer
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.